Search From Over Half a Million Titles


Pharmaceuticals and Healthcare » Pharmaceuticals » Pharmaceuticals

Schizophrenia - Market Insights, Epidemiology and Market Forecast – 2025

  • ID:RM0034238
  • Published: September-2017
  • Pages:70
  • DelveInsight
1 of 3

DelveInsight’s “Schizophrenia - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Schizophrenia - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.

This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Schizophrenia - Market Insights, Epidemiology and Market Forecast. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Schizophrenia - Market Insights, Epidemiology and MarkShow More

1 of 3

1. Report Introduction
2. Schizophrenia Market Overview at a Glance
2.1. Total Market Share Distribution of Schizophrenia for 7 MM in 2016
2.2. Total Market Share Distribution of Schizophrenia for 7 MM in 2025
3. Schizophrenia
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Schizophrenia in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Schizophrenia in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Schizophrenia in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Schizophrenia in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Schizophrenia in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Schizophrenia in United Kingdom
5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices
6. Marketed Drugs for Schizophrenia
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. Overview of Total Schizophrenia Market (2016 & 2025)
9. Schizophrenia: Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. Market Drivers
11. Market Restraints
12. Appendix
13. Report Methodology
14. Consulting Services
15. Disclaimer
16. About DelveInsight


List of Tables

Table 1: Diagnosed Cases Schizophrenia in United States (2015-2025)
Table 2: Diagnosed Cases Schizophrenia in Germany (2015-2025)
Table 3: Diagnosed Cases Schizophrenia in France (2015-2025)
Table 4: Diagnosed Cases Schizophrenia in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Schizophrenia in Spain (2015-2025)
Table 6: Diagnosed Cases Schizophrenia in Italy (2015-2025)
Table 7: Diagnosed Cases Schizophrenia in Japan (2015-2025)
Table 8: List of Marketed Drugs for Schizophrenia
Table 9: List of Pipeline Phase III Drugs for Schizophrenia
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Schizophrenia in USD, Million (2015-2025)
Table 17: Germany Market Size of Schizophrenia in USD, Million (2015-2025)
Table 18: France Market Size of Schizophrenia in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Schizophrenia in USD, Million (2015-2025)
Table 20: Spain Market Size of Schizophrenia in USD, Million (2015-2025)
Table 21: Italy Market Size of Schizophrenia in USD, Million (2015-2025)
Table 22: Japan Market Size of Schizophrenia in USD, Million (2015-2025)

List of Figures
Figure 1: Diagnosed Cases Schizophrenia in United States (2015-2025)
Figure 2: Diagnosed Cases Schizophrenia in Germany (2015-2025)
Figure 3: Diagnosed Cases Schizophrenia in France (2015-2025)
Figure 4: Diagnosed Cases Schizophrenia in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Schizophrenia in Spain (2015-2025)
Figure 6: Diagnosed Cases Schizophrenia in Italy (2015-2025)
Figure 7: Diagnosed Cases Schizophrenia in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Schizophrenia
Figure 9: List of Pipeline Phase III Drugs for Schizophrenia
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 17: Germany Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 18: France Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 20: Spain Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 21: Italy Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 22: Japan Market Size of Schizophrenia in USD, Million (2015-2025)
Schizophrenia Market (7MM)
Schizophrenia Market forecasting
Schizophrenia Sales forecasting
Schizophrenia Market segments
Schizophrenia Epidemiology
Schizophrenia Pipeline products and technologies
Schizophrenia Competitive landscape
Schizophrenia SWOT analysis
Schizophrenia Market Driver’s and barriers
Schizophrenia Key Companies and Funding


List Of Tables

Table 1: Diagnosed Cases Schizophrenia in United States (2015-2025)
Table 2: Diagnosed Cases Schizophrenia in Germany (2015-2025)
Table 3: Diagnosed Cases Schizophrenia in France (2015-2025)
Table 4: Diagnosed Cases Schizophrenia in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Schizophrenia in Spain (2015-2025)
Table 6: Diagnosed Cases Schizophrenia in Italy (2015-2025)
Table 7: Diagnosed Cases Schizophrenia in Japan (2015-2025)
Table 8: List of Marketed Drugs for Schizophrenia
Table 9: List of Pipeline Phase III Drugs for Schizophrenia
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Schizophrenia in USD, Million (2015-2025)
Table 17: Germany Market Size of Schizophrenia in USD, Million (2015-2025)
Table 18: France Market Size of Schizophrenia in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Schizophrenia in USD, Million (2015-2025)
Table 20: Spain Market Size of Schizophrenia in USD, Million (2015-2025)
Table 21: Italy Market Size of Schizophrenia in USD, Million (2015-2025)
Table 22: Japan Market Size of Schizophrenia in USD, Million (2015-2025)


List of Figures

Figure 1: Diagnosed Cases Schizophrenia in United States (2015-2025)
Figure 2: Diagnosed Cases Schizophrenia in Germany (2015-2025)
Figure 3: Diagnosed Cases Schizophrenia in France (2015-2025)
Figure 4: Diagnosed Cases Schizophrenia in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Schizophrenia in Spain (2015-2025)
Figure 6: Diagnosed Cases Schizophrenia in Italy (2015-2025)
Figure 7: Diagnosed Cases Schizophrenia in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Schizophrenia
Figure 9: List of Pipeline Phase III Drugs for Schizophrenia
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 17: Germany Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 18: France Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 20: Spain Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 21: Italy Market Size of Schizophrenia in USD, Million (2015-2025)
Figure 22: Japan Market Size of Schizophrenia in USD, Million (2015-2025)

1 of 3

Type Delivery Format Details
Hard Copy A printed copy of the report will be shipped to you.
CD-ROM The report will be shipped to you in CD ROM format.
SINGLE USER Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows one specific user access to the product.
SITE LICENSE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all users within a given geographical location of your organization access to the product.
ENTERPRISEWIDE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all employees within your organization in different geographic locations access to the product.
1 - 5 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to five users have access to the product.
1 – 10 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to ten users have access to the product.
1 – 15 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to fifteen users have access to the product.
1 - 5 USERS Online Access (For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to five users have access to the product.
1 - 10 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to ten users have access to the product.
1 - 15 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to fifteen users have access to the product.
1 - 5 USERS Electronic (Excel) The Excel spreadsheet will be emailed to you. The license allows up to five users have access to the product.

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-10 user licence, allowing up to ten users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.